IceCure Medical Gets Israeli Approval for XSense Cryoablation System
Ticker: ICCM · Form: 6-K · Filed: Sep 15, 2025 · CIK: 1584371
Sentiment: bullish
Topics: regulatory-approval, medical-devices, israel
TL;DR
IceCure Medical just got Israeli approval for their new XSense cryoablation system for breast cancer. Big win at home!
AI Summary
On September 15, 2025, IceCure Medical Ltd. announced it received regulatory approval in Israel for its next-generation XSense™ cryoablation system. This approval covers the treatment of breast cancer and other indications, marking a significant step for the company's advanced medical technology in its home market.
Why It Matters
This regulatory milestone in Israel could pave the way for broader adoption of IceCure's XSense system in other markets and for additional cancer indications.
Risk Assessment
Risk Level: medium — Regulatory approvals are positive, but market adoption and commercial success are not guaranteed, and the company operates in a competitive medical device sector.
Key Players & Entities
- IceCure Medical Ltd. (company) — Filer of the report and recipient of regulatory approval.
- XSense™ (product) — The next-generation cryoablation system that received approval.
- September 15, 2025 (date) — Date of the press release announcing the regulatory approval.
- Israel (location) — Country where regulatory approval was granted.
FAQ
What specific indications, beyond breast cancer, does the XSense™ system's Israeli approval cover?
The filing states the approval is for 'breast cancer and other indications,' but does not specify what those other indications are.
When was the press release announcing this approval issued?
The press release was issued on September 15, 2025.
What is the SEC file number for IceCure Medical Ltd.?
The SEC file number is 001-40753.
What form is IceCure Medical Ltd. filing with the SEC?
IceCure Medical Ltd. is filing a Form 6-K.
Where is IceCure Medical Ltd. headquartered?
IceCure Medical Ltd. is headquartered in Caesarea, Israel.
Filing Stats: 324 words · 1 min read · ~1 pages · Grade level 12.5 · Accepted 2025-09-15 08:43:12
Filing Documents
- ea0257350-6k_icecure.htm (6-K) — 18KB
- ea025735001ex99-1_icecure.htm (EX-99.1) — 11KB
- 0001213900-25-087437.txt ( ) — 31KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ICECURE MEDICAL LTD. Date: September 15, 2025 By: /s/ Eyal Shamir Name: Eyal Shamir Title: Chief Executive Officer 3